Jushi (JUSHF): A $177M Tax IOU Bigger Than the Whole Company
🎙 Listen — Q&A podcast
Watch on YouTube ↗RoboSystems Cannabis Coverage · FY2025 10-K (filed March 31, 2026) + Q1 FY2026 10-Q (May 12, 2026) All financials verified live via the RoboSystems SEC graph (CIK 0001909747); market data priced late June 2026.
The Hook
In 2025, Jushi Holdings booked a $35.0 million income-tax bill on a $33.6 million pretax loss. Read that again: a company that lost money before taxes still owed the government thirty-five million dollars. That is Section 280E — the tax code written for drug traffickers — doing exactly what it was designed to do.
But here's the part nobody talks about. Of that $35 million tax expense, Jushi paid just $2.45 million in actual cash. The other thirty-two million went onto a pile of unpaid, contested taxes that now totals $177.2 million — nearly double the company's entire $96 million stock-market value. Jushi has spent three years quietly financing itself with an interest-bearing IOU to the IRS. That IOU is the single most important number in this story, and almost no one is looking at it.
Company Snapshot
Jushi is a vertically integrated multi-state operator headquartered in Boca Raton, Florida, trading on the OTCQX as JUSHF (and the CSE as JUSH). It runs 42 Beyond Hello dispensaries plus five grower-processor facilities across eight states. Its center of gravity is the East Coast: Pennsylvania is by far the biggest market — 18 of the 42 stores — and Virginia (6 stores) the most profitable, both limited-license medical-only markets today, rounded out by adult-use Illinois, Nevada, Massachusetts and a fast-growing Ohio. That medical tilt matters more than ever in 2026: management says roughly 60% of 2025 revenue was medical — which, as we'll see, puts Jushi first in line for the tax relief that just arrived. The numbers come from the FY2025 10-K (filed March 31, 2026), updated through the Q1 FY2026 10-Q and the May 12 earnings call; Jushi is also redomiciling its parent from British Columbia to Nevada to tee up future capital-markets options. Revenue is small by MSO standards — about $263 million — and stable. The drama is entirely below the gross-profit line.
The Financial Story
Start with what works. Jushi's operating business is healthy and getting healthier. FY2025 gross margin was 43.4% and Q1 2026 expanded to 45.0%; management credits better cultivation yields and potency. Company-reported adjusted EBITDA reached $50.3 million on a 19.1% margin — up from $46.2 million the year before — and Q4 adjusted EBITDA jumped 74% year-over-year. Operating cash flow was positive $17.7 million, and after $16.1 million of capex the company still squeezed out positive free cash flow. For a sub-$100M-market-cap cannabis name, that is a genuinely functional operation.
Now the two anchors dragging it under. The first is 280E. Because cannabis is Schedule I, Jushi can deduct cost of goods sold but almost nothing else — so the IRS taxes a number close to gross profit even when the company posts a net loss. The result is a tax bill that barely moves with profitability: roughly $31.8M (2023), $31.6M (2024), and $35.0M (2025) — nearly $98 million over three years against cumulative pretax losses of about $84 million. A normal business with those losses pays zero and banks tax-loss carryforwards. Jushi paid the equivalent of a phantom profit's worth of tax on real losses.
The second anchor is the balance sheet. Interest expense was $40.8 million in 2025 — 15.5% of revenue — on roughly $206 million of term debt plus another $65 million of finance leases. Adjusted EBITDA of $50.3 million covers that interest only about 1.2 times. Years of impairments and losses have driven the accumulated deficit to $627 million, leaving negative shareholders' equity of $115 million. Book value is gone; the stock trades on enterprise value and option value, not on equity in the ground.
Here is where the two anchors connect — and where the story gets interesting. That $35 million tax expense is mostly non-cash. Jushi paid only $2.45 million of it in cash in 2025 and parked the rest in a balance-sheet line called unrecognized tax benefits, which swelled from $143.7 million to $177.2 million in a single year. In plain English: Jushi books the 280E tax to keep its filings honest, but defers and contests most of the actual payment. That's why operating cash flow can be positive while GAAP earnings are deeply negative. The catch is that $177 million doesn't disappear — it sits there, larger than the company's market cap and larger than its term debt, waiting for a resolution that could break either way.
Catalyst Scenarios — How the Math Changes
280E relief — and the part that's already happening. Here's what most coverage of this sector misses for a name like Jushi: relief isn't purely hypothetical anymore. The medical-only Schedule III order that took effect April 28, 2026 removes 280E from medical income — and management says about 60% of Jushi's revenue is medical. So Jushi is one of the biggest beneficiaries of a change that has already arrived; the CEO told investors he expects it to "positively impact our tax expense on an ongoing basis." That relief lands starting in the second quarter of 2026 (the first quarter closed March 31, before the effective date), so the place to watch is the Q2 effective tax rate. The second leg — a broad Schedule III order, the subject of the DEA hearing that opens June 29, 2026 — would lift 280E from the remaining ~40% of adult-use income too. On full-year 2025 numbers, removing the entire ~$35 million tax turns a $68.6 million net loss into roughly a $34 million loss, and stops the ~$32 million a year piling onto the unpaid-tax mountain. Be honest about the ceiling, though: even full relief halves the loss rather than creating a profit — with the tax gone, the binding constraint becomes the $40.8 million interest bill.
The back-tax overhang (the swing factor nobody prices). The April relief is prospective, and the IRS is actively clawing back retroactive refund claims across the sector. So Jushi's $177 million reserve is not a refund waiting to happen; it's a contingent liability for tax positions Jushi has already taken — the company explicitly elected to treat its 280E deductions as an "uncertain tax position," which is precisely why it deducts on its returns (tiny cash tax) but books a growing GAAP reserve. The underlying balance has compounded from $104.6 million at the start of 2024 to $167.4 million at the end of 2025 (before interest and penalties). If a broad order lets that balance stop growing and it ages out favorably, $177 million of overhang lifts off a $96 million equity. If the IRS enforces collection instead, the thin equity is in serious trouble. This one line item swings the equity more than any operating metric.
State catalysts — Virginia is back on, the messy way. Jushi's whole thesis rests on its two medical strongholds, Pennsylvania and Virginia, eventually flipping to adult use. Virginia just took the scenic route there: the legislature passed an adult-use bill, Governor Spanberger vetoed it on May 19, 2026, and then — rather than wait another year — the two sides cut a budget compromise that the legislature passed on June 22, 2026, reviving adult-use with retail sales now targeted for July 1, 2027 and up to 350 licenses issued in phases. The start slipped six months from the original January 1 date and still has to survive final budget enactment and a licensing build-out, but the catalyst is alive and dated again. That matters enormously for Jushi, because it built six "superstore" dispensaries in Northern Virginia explicitly designed to flip to adult use and is racing cultivation capacity up (from five grow rooms to eight, plus a new warehouse that roughly doubles output) to meet it — management frames these in-footprint investments as deploying capital at roughly 1–2x EBITDA. Pennsylvania (SB 49) is the next domino but hasn't passed. And a cleaner, already-firing tailwind is the hemp crackdown: after Ohio restricted intoxicating-hemp products in March 2026, Jushi's Ohio revenue grew ~26% year-over-year in April as demand migrated into licensed dispensaries; the federal hemp loophole closes nationwide in November 2026.
Survival and consolidation. Post-year-end, Jushi refinanced into a single $160 million first-lien term loan — a 12.5% coupon, interest-only, maturing in 2029 — that repaid the old first and second lien and, crucially, cleared an $86 million second-lien wall that was due in 2027. Near-term maturities now total only ~$40 million through 2028 against ~$42 million of cash, and the deal was done with no warrants and no equity dilution (the CEO personally added capital). The cost is steep — 12.5% is expensive money — but the acute solvency question that produced going-concern warnings in Jushi's 2023–24 filings is off the table. With 2026 capex guided to just $9–13 million, free cash flow should improve. At a $96 million market cap, Jushi is more plausibly a target than a buyer; its limited-license Pennsylvania and Virginia assets are the kind of incumbency a larger MSO or an outside entrant might pay for.
Valuation — What It's Worth If It's a Normal Business
The first thing to understand is that Jushi is not statistically cheap on enterprise value. At roughly $357 million EV against $50.3 million adjusted EBITDA, it trades near 7.1x — already above the ~4.7x Tier-1 MSO average. The leverage is why: a small equity sliver sits on top of a large, complex liability stack. The cheapness lives entirely in the equity, which at ~$96 million is just 0.35 times sales — among the lowest in the coverage set. You are not buying a cheap business; you are buying a cheap, highly levered option on that business.
Run the re-rating math and the knife-edge is obvious. Apply a CPG-lite 10x multiple to 280E-normalized adjusted EBITDA and enterprise value lands near $500 million; subtract roughly $260 million of net debt and the equity is worth on the order of $240 million — about 2.5 times today's price. But subtract the $177 million tax reserve as a real claim and that same equity is worth less than today's price. The entire bull case rests on one assumption: that the back-tax overhang is resolved, forgiven, or simply never collected.
So the implied-value band — framed as implied value under stated assumptions, not a price target — is unusually wide. In a base case (280E persists, refinanced but levered, the tax reserve looms), the equity is worth roughly where it trades or less. In a partial-catalyst case (a broad Schedule III order lifts 280E prospectively, Virginia adult-use launches, the reserve stops growing), the option moves meaningfully into the money. In a full-catalyst case (broad relief and a favorable resolution of the $177 million reserve and a CPG-style re-rate), the upside is several times the current price. The distance between those outcomes is enormous, and it is governed far more by Washington and the IRS than by anything happening in Jushi's grow rooms.
Risks and Open Questions
The risks here are concrete, not boilerplate. Rescheduling could stall: the partial medical-only order is under a pending D.C. Circuit challenge, the June 29 hearing is stacked with opponents, and broad (adult-use) relief is not guaranteed. The $177 million tax reserve could be enforced rather than forgiven — the IRS is already clawing back retroactive claims sector-wide — which would be acute for a company with negative equity. Leverage is real and expensive: the new first-lien loan carries a 12.5% coupon, adjusted EBITDA covers interest barely over once, and a disputed $21.5 million Sammartino acquisition note sits inside the debt stack. Virginia's July 2027 launch can still slip — it rides on final budget enactment and a phased licensing rollout, and Pennsylvania hasn't passed at all. And the equity is a negative-book, thinly traded OTC microcap — small absolute moves in the liability stack swing it disproportionately. The open questions worth tracking: does the Q2 2026 effective tax rate actually fall now that medical relief is in effect (Q1 closed before the April 28 date, so it wouldn't have shown yet), and does that $177 million reserve finally stop compounding?
The Bottom Line
Jushi is a functioning operator wrapped in a balance sheet built by a punitive tax code. The operating business throws off cash, margins are improving, the debt wall just got pushed to 2029 with no dilution, and — because roughly 60% of its revenue is medical — the relief that took effect in April should start cutting its tax bill this year. But three years of paying tax on losses have left a $177 million unpaid-tax liability — bigger than the company itself — and a $115 million equity deficit. That makes JUSHF less a bet on dispensaries and more a leveraged option on a stack of catalysts firing in sequence: medical 280E relief now, a broad Schedule III order that ends 280E for adult-use income next, a benign resolution of the back-tax mountain, and Virginia adult-use sales arriving around July 2027. If they line up, a $96 million equity has room to re-rate several-fold. If the broad order stalls and the IRS comes for that reserve, the leverage cuts the other way. Watch the Q2 effective tax rate, watch that $177 million line, and watch Virginia. That's the framework — not a recommendation.
This analysis was built with RoboSystems — open-source, structured SEC filing data for every public company. Set up the same tools in about five minutes at robosystems.ai. New customers get 50% off your first month with code CANNABIS50.